Coral is conducting a large study comparing and predicting the relative effectiveness of different medications for autoimmune patients. Patients with Inflammatory Bowel Disease (IBD) who have been diagnosed with either Ulcerative Colitis or Crohn's Disease and are undergoing treatment are eligible to participate. Patients with Rheumatoid Arthritis (RA) and Psoriasis (Ps) will also be enrolled. A novel clinical test will be performed to predict the responsiveness of a particular patient to different immune modulating therapies used in these conditions.
Study Type
OBSERVATIONAL
Enrollment
200
A novel clinical test to predict autoimmune medication response
Coral Genomics, Inc.
San Francisco, California, United States
Prediction of medication response
AUC measure
Time frame: retrospective and 6 months prospectively
Prediction of disease severity
R-squared measure of predicting current disease severity measure
Time frame: at enrollment
Classification of disease
AUC measure at determining the diagnosis/disease of a patient
Time frame: at enrollment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.